Purpose: In an attempt to increase the local concentration of tamoxifen in estrogen receptor positive breast cancer cells, we have prepared and characterized poly(İ-caprolactone) (PCL) nanoparticle formulation. Methods: PCL (mol wt 14,800 daltons) nanoparticles were prepared by the solvent displacement method in acetonewater system in the presence of Pluronic F-68. PCL nanoparticles, labeled with rhodamine123, were incubated with MCF-7 estrogen receptor positive breast cancer cells to determine uptake, intracellular distribution, and localization as a function of time. Intracellular drug concentrations over a specified period of time using different initial doses were examined using tritiated [ 3 H]-tamoxifen. Results: A significant fraction of the administered rhodamine123-loaded PCL nanoparticles was found in the perinuclear region of the MCF-7 cells, where estrogen receptors are also localized, after 1 hour of incubation. Measurements of the intracellular concentrations revealed that most of the administered nanoparticle dose was internalized within the first 30 minutes of incubation, and the uptake followed saturable transport kinetics. Conclusion: Results of this study show that PCL nanoparticles were rapidly internalized in MCF-7 cells and intracellular tamoxifen concentrations followed a saturable process. This approach may provide better therapeutic benefit by delivering the drug locally, near the tumor cells, for a longer period of time.
INTRODUCTION
Purpose: In an attempt to increase the local concentration of tamoxifen in estrogen receptor positive breast cancer cells, we have prepared and characterized poly(İ-caprolactone) (PCL) nanoparticle formulation. Methods: PCL (mol wt 14,800 daltons) nanoparticles were prepared by the solvent displacement method in acetonewater system in the presence of Pluronic F-68. PCL nanoparticles, labeled with rhodamine123, were incubated with MCF-7 estrogen receptor positive breast cancer cells to determine uptake, intracellular distribution, and localization as a function of time. Intracellular drug concentrations over a specified period of time using different initial doses were examined using tritiated [ 3 H]-tamoxifen. Results: A significant fraction of the administered rhodamine123-loaded PCL nanoparticles was found in the perinuclear region of the MCF-7 cells, where estrogen receptors are also localized, after 1 hour of incubation. Measurements of the intracellular concentrations revealed that most of the administered nanoparticle dose was internalized within the first 30 minutes of incubation, and the uptake followed saturable transport kinetics. Conclusion: Results of this study show that PCL nanoparticles were rapidly internalized in MCF-7 cells and intracellular tamoxifen concentrations followed a saturable process. This approach may provide better therapeutic benefit by delivering the drug locally, near the tumor cells, for a longer period of time.
One of the major problems facing cancer chemotherapy is administering the required therapeutic concentration of the drug at the tumor site for the desired period of time without causing undesirable effects on other organs after systemic administration. [1] [2] [3] The tumor vasculature, formed by hypersecretion of angiogenic factors, is highly disorganized and tortuous and serves as a major barrier to drug transport. Tumors also have a very high interstitial hydrostatic pressure, which prevents drug entry into the core. Furthermore, the lack of a functional lymphatic system in tumors allows the drug oozing out of the mass to be diluted in the surrounding tissues and fluids. 4, 5 Targeted drug delivery to solid tumors, therefore, is necessary in order to achieve optimum therapeutic outcomes.
Oral administration of the nonsteroidal anti-estrogen tamoxifen is the treatment of choice for patients with all stages of estrogen receptor positive breast cancer. 6 Tamoxifen belongs to a class of nonsteroidal triphenylethylene derivatives (Figure 1) and is considered the first selective estrogen receptor modulator. 7, 8 Tamoxifen exhibits a good bioavailability upon oral administration and is mainly employed as a long-term prophylactic therapy in women with high risk for breast cancer and in postmenopausal women. The drug exhibits anti-estrogenic activity by binding to the intracellular estrogen receptor. 9 The tamoxifen-estrogen receptor complex binds with DNA and can alter or block subsequent mRNA transcription and lead to cellular apoptosis. 10 Tamoxifen is also thought to induce a tumoricidal effect on estrogen receptor-negative cells by increasing the secretion of inhibitory growth factors such as TGFȕ. 7, 8 Recent reports have shown that tamoxifen may possess anti-angiogenic activity through its anti-estrogenic effects. Following long-term therapy, tamoxifen has some major side effects, including higher incidence of endometrial cancer, liver cancer, thromboembolic disorders, and development of drug resistance. 12 Tamoxifen resistance has been shown in a variety of cells in vitro as well as in vivo. 13 However, at the present time, there is no clear mechanism to explain the development of resistance. These unwanted side effects of tamoxifen, as well as various barriers to the delivery of the drugs to tumor, call for targeted delivery to the tumor site and enhanced uptake by the tumor cells. One approach to overcome the undesirable side effects of tamoxifen includes the use of biodegradable polymeric nanoparticles for tumortargeted drug delivery. It is known that the tumor vasculature is leaky and possesses an enhanced capacity for the uptake of macromolecules and colloidal drug carriers of up to 400 nm in diameter. This effect is known as the enhanced permeability and retention (EPR) effect. [14] [15] [16] [17] [18] Thus, such a delivery method could improve the selectivity of treatment by increasing the ratio of tamoxifen absorbed by the tumor to tamoxifen absorbed by other tissues, leading to a reduction in the systemic side effects.
MATERIALS AND METHODS

Materials
Cellular Uptake and Distribution of Nanoparticles
Preparation of Rhodamine123-Labeled PCL Nanoparticles -Details of the PCL nanoparticle preparation and characterization are presented in our earlier publication. 20 We have found that rhodamine123-containing PCL nanoparticles can be used to observe the cellular uptake and distribution in MCF-7 cells. The fluorescent nanoparticles also have approximately the same zeta potential values as the tamoxifen-loaded nanoparticles. 20 Rhodamine123, added to the PCL solution in acetone at a final concentration of 1.0% (wt/wt), was thoroughly mixed by stirring at room temperature. Being a hydrophobic fluorescent dye, PCL nanoparticles were efficiently labeled with rhodamine123. After checking the particle size and size distribution with a Coulter N-4 Plus Submicron Particle Sizer (Coulter Corp, Miami, FL), the nanoparticles were washed and freeze-dried.
In the present study, we developed tamoxifen-loaded poly(İ-caprolactone) (PCL) nanoparticles and examined the intracellular uptake and concentrations of the drug in MCF-7 cells. Since MCF-7 cells are not professional phagocytes, we assume that the uptake of nanoparticles is not phagocytosis mediated. Also, a process known as adsorptive pinocytosis mainly performs the capture of macromolecules adherent to the surface membrane. The size of an average pinocytic vesicle is about 100 to 200 nm. 19 We do not expect the uptake of nanoparticles to be mediated by a specific receptor on the surface of the MCF-7 cells. Thus, the PCL nanoparticle system is expected to increase the concentration of drug inside the tumor cells as a result of a nonspecific endocytic process, followed by a gradual release of the drug and binding of tamoxifen to the estrogen receptor around the nucleus to produce the desired antitumor effect.
Cell Culture Conditions -Estrogen receptor positive breast cancer cells (MCF-7), obtained from ATCC, were cultured in modified Eagle's minimum essential medium at 37°C in 5.0% CO 2 atmosphere. When the cells had reached 80% confluency, they were detached from the culture vessels by trypsin-EDTA treatment. For analysis of cellular uptake and distribution, the cells were grown on a glass cover slip in 6-well plates.
Analysis of Cell Uptake and Distribution -After washing the rhodamine123-containing PCL nanoparticle suspension with deionized distilled water, the suspension was diluted with sterile phosphate-buffered saline (PBS) and an aliquot was added to the MCF-7 cells. At specific time intervals, the medium was removed and the plates were washed with sterile PBS. After the final wash, the cells were fixed with 4% paraformaldehyde and individual cover slips were mounted on clean glass slides with Fluoromount-G mounting medium (Southern Biotechnology Associates, Birmingham, AL). The slides were viewed with a Zeiss Axioplan-2 (Thornwood, NY) universal microscope with Improvision Openlab 3.0 software for the uptake and distribution of the nanoparticles. Differential interference contrast (DIC) and fluorescence confocal images were obtained at X100 magnifications and processed using Adobe Photoshop software.
Intracellular Tamoxifen Concentrations
Preparation of [
3 H]-Tamoxifen-Loaded PCL Nanoparticles -Tritiated [
3 H]-tamoxifen-loaded nanoparticles were prepared by dissolving a known amount of the polymer, cold tamoxifen, and the radiolabeled tamoxifen in acetone. We added 10 μCi of the radiolabeled drug to 50 mg of the cold drug in acetone. The final specific activity was 0.2 μCi/mg. The radiolabeled tamoxifen-polymer in acetone was then added to the water-Pluronic F-68 mixture under moderate magnetic stirring to form the nanoparticle suspension. The nanoparticle suspension was subjected to centrifugation and washing steps as previously described. 20 The tamoxifen-loaded PCL pellet was suspended in serumfree cell culture medium. Radioactivity, in counts per minute, was measured from an aliquot of the nanoparticle suspension to get a measure of the initial dose. A known volume of the suspension corresponding to a known initial dose was added to the MCF-7 cells in each well. The experiments were performed with an initial dose of 1.9 μg, 5.6 μg, 13.9 μg, and 25 μg tamoxifen encapsulated in nanoparticles and the equivalent amount of drug as solution per 500 000 cells. Upon addition of the known amounts of the drug in the form of the nanoparticle suspension or solution in serum-free medium to the adhered monolayers of MCF-7 cells in culture, the cells were incubated for fixed time intervals ranging from 30 minutes to 4 hours.
Drug Concentration Analysis -At the end of the incubation period, the medium was removed and the cells were washed twice with sterile serum-free medium to remove any adhering traces of the nanoparticles or the drug. The washings as well as the supernatant were pooled and collected in different tubes. The MCF-7 cells were then lysed with 1.0 mL of a 0.05% (wt/vol) Triton X-100 solution. The cell lysate was placed in 20-mL scintillation vials containing 10 mL of the Scintisafe Econo 1 scintillation cocktail (Fisher Scientific, Pittsburgh, PA). These vials were capped and kept in the dark for 1 hour to allow for quenching before radioactivity measurements. The radioactivity, as counts-perminute, was measured with a TriCarb 1600TR liquid scintillation analyzer (Packard Instrument Co, Meridien, CT). The counts-per-minute were converted into the concentration units (ng of tamoxifen per 500 000 cells) using appropriate calibration curves.
RESULTS AND DISCUSSION
Estrogen receptor positive MCF-7 breast cancer cells were used to examine the efficiency of 100-to 300-nm PCL nanoparticle uptake and distribution. Based on the fluorescence measurements of the supernatant in cell culture studies, we observed that the cells, through nonspecific endocytosis took up a significant fraction of the administered nanoparticle dose. Figure 2 shows the uptake process at different time intervals ranging from 15 minutes to 2 hours. Initially, the nanoparticles were located on the periphery of the cells. After 1 hour of incubation, nanoparticle aggregates were primarily found in the endosome/lysosome complex and were seen traversing though the cytosol. After 2 hours of incubation, the majority of the nanoparticle-containing vesicles were located in the perinuclear region of the cells. The uptake and distribution of free rhodamine123 shows a diffused red color in the entire cytoplasm and discrete fluorescing particles were not observed (results not shown). It is important to note that during the experimental period, the cells remained completely viable ensuring that the PCL nanoparticles did not induce any cytotoxicity. Since the estrogen receptors are located in the periphery of the nuclear membrane, these nanoparticles could provide increased therapeutic benefit by delivering tamoxifen locally, near the receptor site.
Intracellular Tamoxifen Concentrations
The intracellular tamoxifen concentration in MCF-7 cells was measured as counts-per-minute and converted to the amount of drug (in ng) per 500 000 cells. The cell count was performed before each incubation experiment, and the number of cells was standardized to 500 000 cells for the purpose of uniformity in calculations. Tamoxifen base is hydrophobic and practically insoluble in water (solubility is <0.01% at 20°C). Because cell uptake studies were performed in serum-free cell culture medium (which does not contain any surfactant to aid in the dissolution of the drug), we do not expect a significant drug release from the nanoparticles. This expectation is supported by our previous studies in which we attempted to perform in vitro tamoxifen release from the nanoparticles in PBS but could not observe any release of the drug for up to 4 hours. In order to enhance solubility, 0.5% (wt/vol) sodium lauryl sulfate was added to the release medium. (Figure 3A-D) , the intracellular concentrations of tamoxifen increased sharply and a plateau was established within the first 30 minutes of drug administration for all initial doses. At a lower dose of 1.9 μg per 500 000 cells (Figure 3A) , the intracellular concentration of tamoxifen from the nanoparticle formulation was greater than from the drug solution. At 1 hour, for instance, the tamoxifen concentrations from the nanoparticles and solution were 460 ng/500 000 cells and 390 ng/500 000 cells, respectively. Almost 38% of the administered dose was delivered intracellularly in 1 hour in the nanoparticle formulation compared with 30% of the dose from the solution.
When the tamoxifen dose was increased to 5.6 μg and above, however, the intracellular concentrations from the nanoparticle formulations were significantly lower than from the solution. At a dose of 13.9 μg ( Figure  3C) , the intracellular tamoxifen concentrations from the nanoparticle formulation and the solution were 1000 ng/500 000 cells and 2200 ng/500 000 cells, respectively, after 1 hour of incubation. This corresponds to 10% and 22% of the initial dose delivered in the nanoparticle and solution formulations, respectively. A Student t test (2-tailed-unequal variance) was performed on the plateau intracellular concentrations (from 1 hour onward) for each of the initial doses in Figure 3A -D. Statistical comparison of the intracellular tamoxifen concentrations showed that there was a significant difference (P < .01) when the drug was administered in solution and PCL nanoparticle formulations.
Since, we assume that the cellular uptake of PCL nanoparticles is primarily mediated by nonspecific endocytotic process, we expect that the nanoparticle transport will follow saturable kinetics. Based on saturation of the endocytotic process for the nanoparticles, the intracellular tamoxifen concentration from the formulation was significantly lower at higher doses. The cellular uptake of drug from the solution, on the other hand, can occur by multiple pathways including passive diffusion and pinocytosis. It is important to note that in vivo, the drug solution will be distributed all over the body, whereas the nanoparticles of 100 to 300 nm may be preferentially distributed in the tumor tissue because of the EPR effect. [14] [15] [16] [17] [18] Under those conditions, the nanoparticle formulations can be very efficient in intracellular delivery of anticancer drugs such as tamoxifen. Astier et al 21 examined the intracellular sustained release of doxorubicin administered in polymethylmethacrylate nanosphere formulation on U-937 cells. Through drug efflux studies, they observed that the nanoparticle formulation provided sustained intracellular doxorubicin concentrations over time as compared with the drug in solution. In addition, the release of drug from the nanosphere formulation followed a biphasic pattern, in which the weakly bound drug was released quickly followed by sustained release of the more strongly bound drug to the carrier system. Although the concentration of doxorubicin inside the cell is expected to be lower from the nanoparticles as compared solution, the continuous exposure of the drug from nanoparticles inhibited cell proliferation to a larger extent than from solution.
The area-under-the-curve (AUC) of the intracellular concentration versus time profiles can be used to compare the extent of drug uptake from the nanoparticle formulation to that in solution. In Figure 4 , the AUC values of tamoxifen delivered in the nanoparticle and the solution formulations are plotted as a function of the administered dose. AUC was calculated using the trapezoidal rule. These results also confirm that the uptake from the nanoparticle formulation was lower at increasing dose compared with the drug in solution. From Figure 3A -D, we found that the maximum rate of uptake for any initial concentration occurs in the first 30 minutes and plateaus after 1 hour. The intracellular drug concentrations, however, increase with an increase in initial dose, which corresponds to a higher AUC value for higher initial doses. Thus, if an increased concentration of the particles is made available to the cells, the net intracellular drug concentration increases.
CONCLUSION
In the present study, we have examined the uptake and distribution of PCL nanoparticles in MCF-7 estrogen positive breast cancer cells and the intracellular tamoxifen concentrations upon administration in the nanoparticle formulations. The MCF-7 cells readily internalize PCL nanoparticles (probably, by nonspecific endocytosis). Intracellular tamoxifen concentration versus time studies showed that the uptake of drug in nanoparticle formulation followed saturable transport. Since tumor vasculature in vivo allows for enhanced retention and uptake of the nanoparticles, this type of delivery system may provide better therapeutic benefit by localizing the drug in the vicinity of the cancer cells. 
